1. Congenital Pulmonary Vein Stenosis: Encouraging Mid-term Outcome.
- Author
-
Charlagorla P, Becerra D, Patel PM, Hoyer M, and Darragh RK
- Subjects
- Angioplasty, Balloon mortality, Child, Preschool, Constriction, Pathologic, Dilatation, Pathologic, Female, Follow-Up Studies, Humans, Infant, Male, Pulmonary Veins surgery, Pulmonary Veno-Occlusive Disease congenital, Pulmonary Veno-Occlusive Disease mortality, Retrospective Studies, Survival Analysis, Survival Rate, Treatment Outcome, Angioplasty, Balloon methods, Pulmonary Veins abnormalities, Pulmonary Veno-Occlusive Disease surgery
- Abstract
Congenital pulmonary vein stenosis (PVS) is a rare entity with limited outcome literature. Multiple interventional approaches have evolved including surgical and catheterization techniques. Our objective is to report our center experience and to compare short-term and mid-term outcomes among these therapeutic modalities. Retrospective study on 23 patients (n = 23) with PVS that required intervention over the last 13 years (2000-2013). Patients were divided into three groups based on type of initial intervention. Of these, 10 (43.5%) had balloon angioplasty, 3 (13.0 %) had surgical dilation, and 10 (43.5%) had surgical marsupialization. Mortality and number of re-interventions were our primary outcomes. Mean age at diagnosis was 10.9 ± 18.4 months. Mean age at initial intervention was 14.5 ± 18.0 months. Mean pre- and post-initial intervention PVS gradients were 9.2 ± 3.4 and 3.4 ± 2.2 mmHg, respectively. Mean survival time and re-intervention-free survival time were 4.8 ± 4.0 and 2.8 ± 3.4 years. No statistical significance was found between the interventions with respect to survival time (p = 0.52) and re-intervention free time (p = 0.78). High initial pre- and post-intervention gradients were significantly associated with re-intervention-free survival (p = 0.01 and p = 0.03, respectively). Patients with bilateral disease have increased mortality (p = 0.01) and decreased 5-year survival (p = 0.009) compared to patients with unilateral disease irrespective of type of intervention. No statistically significant difference in mortality or re-intervention rate was present among these different therapeutic modalities. This study has the longest follow-up so far reported in the current literature (58 months) with overall survival of 78%.
- Published
- 2016
- Full Text
- View/download PDF